Evidence-based treatment of chronic immune-mediated neuropathies.
Immune-mediated neuropathies are treatable disorders that can result in considerable disability in some cases. Chronic immune-mediated neuropathies include chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy and neuropathy associated with monoclonal gammopathy. In recent years, therapeutic strategies for these disorders have become clearer as a result of large, randomized controlled trials. However, the treatments used can have serious adverse effects and at least 30% of patients do not respond to conventional therapies. The aim of this paper is to review available data on evidence-based immunotherapy of chronic immune-mediated neuropathies and to summarize recent findings and results obtained with new innovative therapies, such as new immunosuppressants and monoclonal antibodies.
Magy
Laurent
L
Service de Neurologie, CHU Limoges, 2 Avenue Martin Luther King, 87042 Limoges Cedex, France. laurent.magy@unilim.fr
Vallat
Jean-Michel
JM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D002908:Chronic Disease; D006801:Humans; D007166:Immunosuppressive Agents / Q000276:immunology / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D016472:Motor Neuron Disease / Q000276:immunology / Q000628:therapy; D010265:Paraproteinemias / Q000276:immunology / Q000628:therapy; D010523:Peripheral Nervous System Diseases / Q000276:immunology / Q000628:therapy*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000276:immunology / Q000628:therapy; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents